Novel anti-infective compounds from marine bacteria

Hafizur Rahman, Brian Austin, Wilfrid J. Mitchell, Peter C. Morris, Derek J. Jamieson, David R. Adams, Andrew Mearns Spragg, Michael Schweizer

Research output: Contribution to journalLiterature review

Abstract

As a result of the continuous evolution of microbial pathogens towards antibiotic-resistance, there have been demands for the development of new and effective antimicrobial compounds. Since the 1960s, the scientific literature has accumulated many publications about novel pharmaceutical compounds produced by a diverse range of marine bacteria. Indeed, marine micro-organisms continue to be a productive and successful focus for natural products research, with many newly isolated compounds possessing potentially valuable pharmacological activities. In this regard, the marine environment will undoubtedly prove to be an increasingly important source of novel antimicrobial metabolites, and selective or targeted approaches are already enabling the recovery of a significant number of antibiotic-producing micro-organisms. The aim of this review is to consider advances made in the discovery of new secondary metabolites derived from marine bacteria, and in particular those effective against the so called "superbugs", including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin resistant enterococci (VRE), which are largely responsible for the increase in numbers of hospital acquired, i.e., nosocomial, infections. © 2010 by the authors; licensee Molecular Diversity Preservation International.

Original languageEnglish
Pages (from-to)498-518
Number of pages21
JournalMarine Drugs
Volume8
Issue number3
DOIs
Publication statusPublished - Mar 2010

Fingerprint

Bacteria
Literature
Aquatic Organisms
Methicillin-Resistant Staphylococcus aureus
Microbial Drug Resistance
Cross Infection
Biological Products
Publications
Pharmacology
Anti-Bacterial Agents
Research
Pharmaceutical Preparations
Vancomycin-Resistant Enterococci

Keywords

  • Antibiotic resistance
  • Hospital superbugs
  • Marine bacteria
  • MRSA
  • New scaffolds
  • Nosocomial infection
  • VRE

Cite this

Rahman, Hafizur ; Austin, Brian ; Mitchell, Wilfrid J. ; Morris, Peter C. ; Jamieson, Derek J. ; Adams, David R. ; Spragg, Andrew Mearns ; Schweizer, Michael. / Novel anti-infective compounds from marine bacteria. In: Marine Drugs. 2010 ; Vol. 8, No. 3. pp. 498-518.
@article{de4b66317e434b309c31a13420f8c296,
title = "Novel anti-infective compounds from marine bacteria",
abstract = "As a result of the continuous evolution of microbial pathogens towards antibiotic-resistance, there have been demands for the development of new and effective antimicrobial compounds. Since the 1960s, the scientific literature has accumulated many publications about novel pharmaceutical compounds produced by a diverse range of marine bacteria. Indeed, marine micro-organisms continue to be a productive and successful focus for natural products research, with many newly isolated compounds possessing potentially valuable pharmacological activities. In this regard, the marine environment will undoubtedly prove to be an increasingly important source of novel antimicrobial metabolites, and selective or targeted approaches are already enabling the recovery of a significant number of antibiotic-producing micro-organisms. The aim of this review is to consider advances made in the discovery of new secondary metabolites derived from marine bacteria, and in particular those effective against the so called {"}superbugs{"}, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin resistant enterococci (VRE), which are largely responsible for the increase in numbers of hospital acquired, i.e., nosocomial, infections. {\circledC} 2010 by the authors; licensee Molecular Diversity Preservation International.",
keywords = "Antibiotic resistance, Hospital superbugs, Marine bacteria, MRSA, New scaffolds, Nosocomial infection, VRE",
author = "Hafizur Rahman and Brian Austin and Mitchell, {Wilfrid J.} and Morris, {Peter C.} and Jamieson, {Derek J.} and Adams, {David R.} and Spragg, {Andrew Mearns} and Michael Schweizer",
year = "2010",
month = "3",
doi = "10.3390/md8030498",
language = "English",
volume = "8",
pages = "498--518",
journal = "Marine Drugs",
issn = "1660-3397",
publisher = "Multidisciplinary Digital Publishing Institute",
number = "3",

}

Novel anti-infective compounds from marine bacteria. / Rahman, Hafizur; Austin, Brian; Mitchell, Wilfrid J.; Morris, Peter C.; Jamieson, Derek J.; Adams, David R.; Spragg, Andrew Mearns; Schweizer, Michael.

In: Marine Drugs, Vol. 8, No. 3, 03.2010, p. 498-518.

Research output: Contribution to journalLiterature review

TY - JOUR

T1 - Novel anti-infective compounds from marine bacteria

AU - Rahman, Hafizur

AU - Austin, Brian

AU - Mitchell, Wilfrid J.

AU - Morris, Peter C.

AU - Jamieson, Derek J.

AU - Adams, David R.

AU - Spragg, Andrew Mearns

AU - Schweizer, Michael

PY - 2010/3

Y1 - 2010/3

N2 - As a result of the continuous evolution of microbial pathogens towards antibiotic-resistance, there have been demands for the development of new and effective antimicrobial compounds. Since the 1960s, the scientific literature has accumulated many publications about novel pharmaceutical compounds produced by a diverse range of marine bacteria. Indeed, marine micro-organisms continue to be a productive and successful focus for natural products research, with many newly isolated compounds possessing potentially valuable pharmacological activities. In this regard, the marine environment will undoubtedly prove to be an increasingly important source of novel antimicrobial metabolites, and selective or targeted approaches are already enabling the recovery of a significant number of antibiotic-producing micro-organisms. The aim of this review is to consider advances made in the discovery of new secondary metabolites derived from marine bacteria, and in particular those effective against the so called "superbugs", including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin resistant enterococci (VRE), which are largely responsible for the increase in numbers of hospital acquired, i.e., nosocomial, infections. © 2010 by the authors; licensee Molecular Diversity Preservation International.

AB - As a result of the continuous evolution of microbial pathogens towards antibiotic-resistance, there have been demands for the development of new and effective antimicrobial compounds. Since the 1960s, the scientific literature has accumulated many publications about novel pharmaceutical compounds produced by a diverse range of marine bacteria. Indeed, marine micro-organisms continue to be a productive and successful focus for natural products research, with many newly isolated compounds possessing potentially valuable pharmacological activities. In this regard, the marine environment will undoubtedly prove to be an increasingly important source of novel antimicrobial metabolites, and selective or targeted approaches are already enabling the recovery of a significant number of antibiotic-producing micro-organisms. The aim of this review is to consider advances made in the discovery of new secondary metabolites derived from marine bacteria, and in particular those effective against the so called "superbugs", including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin resistant enterococci (VRE), which are largely responsible for the increase in numbers of hospital acquired, i.e., nosocomial, infections. © 2010 by the authors; licensee Molecular Diversity Preservation International.

KW - Antibiotic resistance

KW - Hospital superbugs

KW - Marine bacteria

KW - MRSA

KW - New scaffolds

KW - Nosocomial infection

KW - VRE

UR - http://www.scopus.com/inward/record.url?scp=77952481633&partnerID=8YFLogxK

U2 - 10.3390/md8030498

DO - 10.3390/md8030498

M3 - Literature review

C2 - 20411112

VL - 8

SP - 498

EP - 518

JO - Marine Drugs

JF - Marine Drugs

SN - 1660-3397

IS - 3

ER -